Literature DB >> 10571598

The efficacy of octreotide therapy in chronic bleeding due to vascular abnormalities of the gastrointestinal tract.

G Nardone1, A Rocco, T Balzano, G Budillon.   

Abstract

BACKGROUND: The treatment of angiodysplasia and watermelon stomach, vascular abnormalities implicated in gastrointestinal bleeding of obscure origin, is a major clinical problem. AIM: To determine the efficacy of octreotide in patients with long-standing gastrointestinal bleeding due to acquired angiodysplasia and watermelon stomach, resistant to previous treatments and not suitable for surgery because of old age and/or concomitant disorders. PATIENTS AND METHODS: We treated 17 patients (seven had isolated angiodysplasia, seven had multiple upper and lower gastrointestinal angiodysplasia, and three had watermelon stomach) with octreotide (0. 1 mg subcutaneous t.d.s. for 6 months). Six of the patients had liver cirrhosis, one had Glanzmann-type platelet derangement, two had cardiovascular diseases and one had chronic uraemia.
RESULTS: Octreotide treatment stopped bleeding in 10 patients. A transient improvement was observed in four, who needed subsequent cyclical retreatment to correct low haemoglobin levels. No effect was observed in three, probably due to the severity of the concomitant disorders.
CONCLUSIONS: Octreotide is a safe drug that may be useful to control the recurrent gastrointestinal bleeding due to acquired angiodysplasia and watermelon stomach, especially in patients who are not candidates for surgery due to old age and/or concomitant disorders.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10571598     DOI: 10.1046/j.1365-2036.1999.00647.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  42 in total

Review 1.  Portal hypertensive gastropathy and gastric antral vascular ectasia (GAVE) syndrome.

Authors:  K W Burak; S S Lee; P L Beck
Journal:  Gut       Date:  2001-12       Impact factor: 23.059

Review 2.  Non-variceal gastrointestinal bleeding in patients with liver cirrhosis: a review.

Authors:  M Kalafateli; C K Triantos; V Nikolopoulou; A Burroughs
Journal:  Dig Dis Sci       Date:  2012-06-04       Impact factor: 3.199

3.  Octreotide for gastrointestinal bleeding of obscure origin in an anticoagulated patient.

Authors:  Luke T Nordquist; Paul M Wallach
Journal:  Dig Dis Sci       Date:  2002-07       Impact factor: 3.199

4.  Treatment of recurrent gastrointestinal haemorrhage in a patient with von Willebrand's disease with octreotide LAR and propranolol.

Authors:  N Krikis; K Tziomalos; V Perifanis; S Vakalopoulou; A Karagiannis; V Garipidou; F Harsoulis
Journal:  Gut       Date:  2005-01       Impact factor: 23.059

5.  Octreotide LAR for severe obscure-overt gastrointestinal haemorrhage in high-risk patients on anticoagulation therapy.

Authors:  J Molina-Infante; B Perez-Gallardo; G Gonzalez-Garcia; M Fernandez-Bermejo; J M Mateos-Rodriguez; P Robledo-Andres
Journal:  Gut       Date:  2007-03       Impact factor: 23.059

Review 6.  Pharmacological therapy of vascular malformations of the gastrointestinal tract.

Authors:  Andrew Szilagyi; Maged P Ghali
Journal:  Can J Gastroenterol       Date:  2006-03       Impact factor: 3.522

Review 7.  Diagnostic and therapeutic options in obscure gastrointestinal blood loss.

Authors:  R Amaro; J S Barkin
Journal:  Curr Gastroenterol Rep       Date:  2000-10

Review 8.  Continuing challenges in the diagnosis and management of obscure gastrointestinal bleeding.

Authors:  Veronica Baptista; Neil Marya; Anupam Singh; Abbas Rupawala; Bilal Gondal; David Cave
Journal:  World J Gastrointest Pathophysiol       Date:  2014-11-15

Review 9.  Approach to the management of portal hypertensive gastropathy and gastric antral vascular ectasia.

Authors:  Bezawit D Tekola; Stephen Caldwell
Journal:  Clin Liver Dis (Hoboken)       Date:  2012-11-09

Review 10.  Transjugular intrahepatic portosystemic shunts and portal hypertension-related complications.

Authors:  Sith Siramolpiwat
Journal:  World J Gastroenterol       Date:  2014-12-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.